$125M Growth Round Fuels Keyfactor and PrimeKey Merger to Bring Machine Identity Management to the Mainstream
First-Ever Merger Between Certificate Automation and Certificate Authority Providers Set to Impact IAM Strategy for Enterprises
CLEVELAND and STOCKHOLM, Sweden, April 15, 2021 (GLOBE NEWSWIRE) -- Keyfactor® and PrimeKey® today announced their intent to merge under the Keyfactor brand while committing to increased investments across all product lines.
Keyfactor is the pioneer of PKI as-a-Service, and the recognized leader in certificate lifecycle automation and crypto-agility solutions. PrimeKey’s EJBCA® software offers the most powerful and flexible certificate authority (CA) supporting DevOps, IoT, manufacturing and enterprise use cases.
The merger forms an industry-first machine identity management platform, combining Keyfactor’s certificate lifecycle automation with PrimeKey’s EJBCA. The new platform will provide end-to-end machine identity management – with flexible and highly scalable certificate issuance and automated deployment of machine identities across complex enterprise and emerging IoT and OT use cases.
“Now more than ever, enterprises must operate in a zero trust world, and machine identity management can no longer be ignored as part of an identity and access management (IAM) strategy,” explained Jordan Rackie, CEO at Keyfactor. “Keyfactor’s 50% year-over-year growth is a testament to the industry’s imperative to secure every machine identity before it leads to loss of brand reputation, business outages or fines. The merger with PrimeKey amplifies the performance of the combined businesses across product offerings, distribution channels, expertise for our customers and large open source communities.”
Machine identity management was introduced by Gartner in its Hype Cycle for Identity and Access Management Technologies, 2020 report and recognized as a “high” benefit in IAM. Even though machine identities, such as keys, certificates and secrets continue to outnumber human identities (e.g., usernames and passwords), they are often left out of an IAM strategy. Keyfactor customers recognize that cryptography is the critical infrastructure to ensure digital trust and help CISO’s achieve crypto-agility for their digital business.
“Our combined solutions now give customers unparalleled deployment choices including PKI as-a-Service, SaaS PKI (Azure, AWS, GCP), software appliance or FIPS 140-certified hardware,” explained Magnus Svenningson, CEO at PrimeKey. “These flexible deployment options give our customers the control to operate a single pane of glass across all their machine identities in hybrid and multi-cloud environments. Our EJBCA, SignServer and Bouncy Castle solutions are widely adopted by the developer community to integrate security in DevSecOps workflows and will remain open source as we continue to bring cutting-edge innovations to our enterprise customers.”
PrimeKey’s employees will join Keyfactor, creating an unprecedented mashup of talent in the identity management space. Jordan Rackie will continue leading the organization as CEO and Magnus Svenningson will assume the role of chief strategy officer (CSO) and executive vice president (EVP) of business development. The combined company will have a global presence with offices in the U.S., EMEA and Asia-Pacific. The transaction is expected to close within the next 90 days, pending approval by the Swedish authorities.
“The market is recognizing that securing machine identities is a fundamental pillar of a modern identity governance program,” said Thomas Krane, principal at Insight Partners. “The IAM market is shifting its focus from human to machine identities, and this merger positions Keyfactor to stay on the leading edge of this evolution. Independently, Keyfactor and PrimeKey offer a forward-thinking approach to conventional IAM. Combined, the companies deliver a future-proof management solution for every machine identity.”
This $125 million growth infusion, led by Insight Partners, adds to its initial $77 million investment in Keyfactor in 2019.
Keyfactor is the leader in cloud-first PKI-as-a-Service and crypto-agility solutions. Its Crypto-Agility Platform™ empowers security teams to seamlessly orchestrate every key and certificate across their entire enterprise. The company helps its customers apply cryptography in the right way from modern, multi-cloud enterprises to complex IoT supply chains.
With decades of cybersecurity experience, Keyfactor is trusted by more than 500 enterprises across the globe. Built on a foundation of trust and security, Keyfactor is a proud equal opportunity employer, supporter and advocate of growing a trusted, secure, diverse and inclusive workplace. For more information, visit www.keyfactor.com or follow Keyfactor on LinkedIn, Twitter and Facebook.
PrimeKey is one of the world’s leading PKI and signing solutions providers and has developed several innovative products, including EJBCA® Enterprise, SignServer Enterprise, PKI Appliance, PrimeKey SEE and Identity Authority Manager.
As a pioneer in open-source security software, PrimeKey provides global businesses and organizations the ability to implement vital security solutions, such as e-ID, e-Passports, authentication, digital signatures, unified digital identities and validation. PrimeKey products are Common Criteria and FIPS-certified, the company’s internal processes are ISO 9001, 14001 and 27001 certified and it has numerous Webtrust/ETSI and eIDAS-audited customers.
PrimeKey has offices in Stockholm, Sweden; Aachen, Germany; San Mateo, USA; and Melbourne, Australia. With a global network of technology and reselling partners, PrimeKey supports a customer roster that includes industry-leading companies and institutions across the IT, telecommunications, industry, finance and public sectors. For more information, please visit www.primekey.com or follow on LinkedIn and Twitter.
MRB Public Relations (for Keyfactor)
Magnus Svenningson, CEO
Tomas Gustavsson, CTO
Akima Media (for PrimeKey)
Simon A. Löfflad
+49 89 1795918-0
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Mandalay Resources Corporation Announces Financial Results for the First Quarter of 202113.5.2021 00:05:33 CEST | Press release
TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce its financial results for the quarter March 31, 2021. The Company’s condensed and consolidated interim financial results for the quarter ended March 31, 2021, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. First Quarter 2021 Highlights: Quarterly revenue of $52.6 million; highest since Q2 2016;Adjusted EBITDA of $26.1 million; third highest in Company’s history;Adjusted net income of $5.6 million ($0.06 or C$0.08 per share); andConsolidated net income of $25.5 million ($0.28 or C$0.35 per share). Dominic Duffy, President and CEO of Mandalay, commented: “Mandalay Resources is ple
Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy12.5.2021 22:29:11 CEST | Press release
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release of preliminary data relating to the use of a novel cell therapy approach in controlling human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of the Seraph Research Institute (SRI), presented the findings at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Presentation can be found at https://www.enochianbio.com/about-us/collaborations/ A 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy. With approval from an Institutional Review Board, this single patient was treated with a novel cellular therapy of natural killer (NK) and gamma delta T-cells (GDT) – a small subset of immune cells that can be infected with HIV but coul
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases12.5.2021 22:00:00 CEST | Press release
Cash and cash equivalents at €107.8m as of March 31, 2021 Revenues of €0.1m in Q1 2021Decision by AbbVie to move into Phase IIb clinical development with cedirogant in psoriasis, following promising results in its Phase Ib clinical trial Daix (France), May 12, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of March 31, 2021 and its revenues for the first quarter of 2021, and provided an update on its collaboration with AbbVie in auto-immune diseases. Cash Position As of March 31, 2021, Inventiva’s cash and cash equivalents stood at €107.8 million compared to €113.0 million as of December 31, 2020. Net cash used in operating activities amounted to €7.8 million in the first quarter of 2021 compared to €3.6
TGS Shares received by Board of Directors12.5.2021 21:27:41 CEST | Press release
OSLO, Norway (12 May 2021) - The Annual General Meeting of TGS held on 11 May 2021, approved that each of the Directors, other than the Chairman, should receive 1650 restricted shares in the Company as part of their compensation. The shares were transferred to the Directors on 12 May 2021. The attachment shows the number of restricted shares awarded on 11 May 2021 and the total number of shares held by each of the Directors. The Company has distributed the restricted shares to the Directors from its balance of treasury shares. Following the transfer of restricted shares to the Directors, TGS will hold 225,100 of the issued shares as treasury shares. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. Forward Looking Statement All statements in thi
Leasinvest Real Estate intends to become an integrated real estate group through an envisaged business combination with Extensa Group and by giving up its BE-REIT status12.5.2021 19:13:09 CEST | Press release
JAN SUYKENS, CEO ACKERMANS & VAN HAAREN CHAIRMAN LEASINVEST RE: “AvH, which owns today both 30.01% of LRE and 100% of Extensa, is pleased to be able to support the evolution of the Company’s strategy as proposed by its management. Through the contribution of our stake in Extensa, we strengthen our commitment to LRE and we support the intended strategic evolution towards a mixed real estate investment and development group.” MICHEL VAN GEYTE, CEO LEASINVEST RE: “’Leasinvest 2.0’ will become a real estate player with a unique market position that combines the best of both worlds: recurring rental income from real estate investments and added value potential from development activities. In addition, ‘Leasinvest 2.0’ will operate from a thorough sustainability vision in which it will make a lasting contribution to the development and optimization of its real estate portfolio in Belgium, the Grand Duchy of Luxemburg and Austria.” A unique combination Leasinvest Real Estate (the “Company”) a
Volta Finance Limited - Net Asset Value as at 30 April 202112.5.2021 18:17:42 CEST | Press release
Volta Finance Limited (VTA / VTAS) –April2021 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 12May2021 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for April. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY Volta has continued to perform well with +2.1% in April, reaching a total return of 8.4% for the first four months of 2021. In April, Volta paid €0.14 per share dividend to shareholders (circa 8% annualized yield), a €0.02 increase relative to the January dividend payment, evidencing the improving situation of Volta. This time around, the performance was driven almost evenly by the solid performance from CLO equity and CLO debt tranches. This month, contrary to March, the USD depreciation cost almost 1% of the monthly performance. The monthly
Idorsia holds its Annual General Meeting of Shareholders12.5.2021 18:09:53 CEST | Press release
Allschwil, Switzerland – May12, 2021 All Board proposals approved by the Shareholders At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Allschwil, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with a large majority. The meeting was held in accordance with the requirements of the COVID‑19 Ordinance 3, issued by the Swiss Federal Council. As a result, attendance in person was not possible and voting took place by independent proxy. In total, 4,541 shareholders voted through the independent proxy, representing a total of 112,170,657 shares, or 67.13% of the total outstanding shares. Mathieu Simon, MD, Chairman of the Board of Directors of Idorsia, commented: “Despite the global pandemic, Idorsia looks back on an incredibly successful year and the future promises to not lose any momentum. The coming year will be crucial as we continue to build the foundation of Idorsia's future. I am very proud to have been re-elected as your C